Sheep And Goat Pox Vaccines Global Market Report 2024

Sheep and goat pox vaccines are specifically developed to prevent diseases caused by viruses belonging to the Capripoxvirus genus, which include sheep pox and goat pox. These vaccines play a critical role in preventing and managing outbreaks among sheep and goat populations, as both diseases can lead to significant economic losses due to high mortality rates and reduced productivity. They function by stimulating the immune system to generate antibodies against the viruses, thereby providing protection from infection.

The primary types of sheep and goat pox vaccines include live attenuated vaccines, inactivated vaccines, and others. Live attenuated vaccines use weakened forms of the virus to stimulate the immune system without causing severe illness. They are particularly effective for diseases such as sheep and goat pox where a robust immune response is necessary for effective protection. These vaccines are administered via various routes such as injectable and intranasal applications for sheep and goats.

The sheep and goat pox vaccines research report is one of a series of new reports that provides sheep and goat pox vaccines market statistics, including the sheep and goat pox vaccines industry's global market size, regional shares, competitors with a sheep and goat pox vaccines market share, detailed sheep and goat pox vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the sheep and goat pox vaccines industry. This sheep and goat pox vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sheep and goat pox vaccine market size has grown steadily in recent years. It will grow from $55.28 billion in 2023 to $57.79 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The growth observed in the historic period can be attributed to several factors such as heightened occurrences of sheep and goat pox, government vaccination initiatives, advancements in veterinary medicine, elevated livestock mortality rates, improved farmer awareness, economic losses from diseases, trade limitations in affected regions, enhanced diagnostic techniques, historical disease prevalence, and collaboration among veterinary institutions.

The sheep and goat pox vaccine market size is expected to see steady growth in the next few years. It will grow to $69.36 billion in 2028 at a compound annual growth rate (CAGR) of 4.7%. The anticipated growth in the forecast period is driven by increasing demand for livestock products, expansion of livestock farming, government subsidies supporting vaccines, greater investments in veterinary research, technological advancements in vaccine production, heightened awareness of animal health, international trade agreements, the influence of climate change on disease dynamics, the emergence of novel vaccine technologies, economic growth in developing areas. Key trends in the forecast period include the development of multivalent vaccines, rising use of recombinant vaccines, heightened focus on vaccine safety, expansion of public-private partnerships, growth in the veterinary vaccine market, digital tracking of vaccination campaigns, increased funding for animal health research, regional disease eradication efforts, adoption of sustainable farming practices, and strengthened regulatory frameworks for vaccines.

The increasing demand for livestock products is poised to drive growth in the market for sheep and goat pox vaccines. Livestock products encompass various goods derived from domesticated animals raised in agricultural settings. This rising demand stems from factors such as income and population growth, urbanization, health considerations, evolving consumer preferences, globalization, trade, and economic development. Sheep and goat pox vaccines play a crucial role in protecting livestock products by preventing disease outbreaks and ensuring the health and productivity of sheep and goat populations. For example, in February 2024, the Department for Environment, Food, and Rural Affairs noted an increase in red meat production, particularly mutton and lamb, with the largest rise recorded at 2.9%. Additionally, total domestic fish production in 2022 slightly exceeded 4.18 billion metric tons, up from 4.17 billion metric tons in 2020. Hence, the growing demand for livestock products is expected to drive expansion in the sheep and goat pox vaccines market.

Key companies in the sheep and goat pox vaccines market are actively developing innovative products, such as live attenuated vaccines, to bolster disease prevention and livestock health. Live attenuated vaccines for goat pox employ weakened virus strains to stimulate immunity without causing disease. For instance, in December 2021, Indian Immunologicals Ltd. (IIL), an India-based vaccine manufacturer, launched Raksha Goat Pox, a live attenuated vaccine (Uttarkashi strain) cultivated on Vero cell culture. This vaccine aims to combat goat pox disease in India, which holds significant economic importance for rural livestock farmers. Primary vaccination is administered at 3 months of age, followed by annual revaccination with a 1 ml subcutaneous dose.

In September 2022, Hester Biosciences Limited, an India-based animal healthcare company, acquired the manufacturing technology for the Goat Pox vaccine (Uttarkashi Strain) from the Indian Veterinary Research Institute (IVRI) for an undisclosed sum. This acquisition enables Hester to supply the goat pox vaccine through state government tenders for cattle immunization against lumpy skin disease in various states. The Indian Veterinary Research Institute, a prominent institution for livestock research and development in India, facilitated this technology transfer.

Major companies operating in the sheep and goat pox vaccines market are Indian Immunologicals Ltd., Kemin Industries, Bimeda Biologicals, Hester Biosciences Limited, Dollvet, MSD Animal Health, MCI Santé Animale, Creative Biolabs, Biovex Inc., Advacare Pharma, Brilliant Bio Pharma Private Limited, Intervac (PVT) Ltd., Agrinnovate India Limited, Bio-Med Pvt Limited, JOVAC, Vetal Animal Health Products, Kenya Veterinary Vaccines Production Institute, Vedall Pharma Private Limited, Farmer's Pharma Private Limited, Institute of Veterinary Biological Products.

North America was the largest region in the sheep and goat pox vaccines market in 2023. The regions covered in the sheep and goat pox vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sheep and goat pox vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sheep and goat pox vaccines market consists of sales of recombinant vaccines and subunit vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.